US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Follicum's Phase II study with FOL-005 for treatment of Alopecia approved by the German Medicines Agency

Follicum AB ("Follicum" or "the Company") today announces that it has received approval from the German Medicines Agency (BfArM) and the German Ethics Committee to start a Phase IIa clinical study with a topical formulation of FOL-005 on patients with alopecia (hair loss). The trial will comprise about 200 patients who will be treated with FOL-005 or placebo daily for 4 months. The study is conducted in collaboration with the Charité Clinical Research Center for Hair and Skin Science ("CRC") in Berlin and proDERM, Hamburg, Germany.In two previous clinical studies, FOL-005 has been shown to

Follicum AB announces that all patients have completed the treatment with FOL-005 in the Phase IIa study against hair loss.

Top-line data will be presented in the autumn. Follicum AB ("Follicum" or "The Company") today announces that all patients in the ongoing Phase IIa study with FOL-005 for hair loss have completed the treatment and finalized clinic visits. The Phase IIa study examines the safety and therapeutic effect of various doses of drug candidate FOL-005, administered as injections into the scalp.Follicum’s Phase IIa study is being conducted at the Clinical Research Center for Hair and Skin Science ("CRC") in Berlin and at Bioskin, Hamburg, Germany. The study is blinded, and results will not be

Follicum’s Phase IIa Hair Growth Study Fully Recruited

Follicum AB (“Follicum” or “the Company”) today announced that all patients in the Phase IIa clinical trial with FOL-005 for stimulating hair growth have been recruited. The trial is conducted at the Clinical Research Center for Hair and Skin Science (“CRC”) in Berlin and Bioskin, Hamburg, Germany. The objective is to investigate the safety and effect of different doses of the drug candidate FOL-005 on scalp.FOL-005 is a modified, short version of the endogenous protein, osteopontin. In the recently completed phase I/IIa study, FOL-005 was shown to be a safe and effective treatment, with 3

Follicum AB Announces more than 50% Recruitment Reached In FOL-005 Phase IIa Hair Growth Study

Follicum AB (“Follicum” or “the Company”) today announced that more than half of the patients in the new Phase IIa clinical trial with FOL-005 for stimulating hair growth have been recruited. In the trial conducted at the Clinical Research Center for Hair and Skin Science (“CRC”) in Berlin and Bioskin, Hamburg, Germany, 60 patients with hair loss will be included. The trial investigates the safety and effect of different doses of the drug candidate FOL-005 on scalp.FOL-005 is a modified, short version of the endogenous protein, osteopontin. In the recently completed phase I/IIa study, FOL-

First patient treated in Follicum’s Phase IIa study of FOL-005 for stimulation of hair growth

Lund, Sweden, March 7, 2018: Follicum AB (“Follicum” or “the company”) today announced that the first patient has been treated in the Phase IIa clinical trial in Germany with its lead candidate FOL-005 on 60 patients with hair loss. The study is conducted at Clinical Research Center for Hair and Skin Science (“CRC”) in Berlin and bioskin, Hamburg, Germany. The global market for pharmaceutical hair loss products for both men and women is estimated to be worth $3 billion. The available drug products have unwanted side-effects that limit their use.FOL-005 is a modified short version of the

Follicum Phase IIa study of FOL-005 against hair loss approved by the German Medicines Agency

Lund, Sweden, February 7, 2018: Follicum AB (“Follicum” or “the company”) today announced it has received approval from the German Medicines Agency (BfArM) and German Ethics Committee to commence a Phase IIa clinical trial in Germany with its lead candidate FOL-005 on patients with Alopecia (hair loss). The trial will include approximately 60 patients and be run in collaboration with the Clinical Research Center for Hair and Skin Science (“CRC”) in Berlin and bioskin, Hamburg, Germany. Currently there are no effective products available for men and women in what is estimated to be a global

There are no items matching the current filter
There are no more items matching the current filter
Back to top